Christopher Holroyd

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby, Patrick Durez, Maya H Buch et al. · The Lancet · 2021 · 285 citations · Full text

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

Christopher Holroyd, Rakhi Seth, Marwan Bukhari et al. · Lara D. Veeken · 2018 · 166 citations · Full text

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 84 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome

Christopher Holroyd, Justin H. Davies, P Taylor et al. · Osteoporosis International · 2010 · 71 citations

Bone Disease, Bone Health, Turner Syndrome +6

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis—Executive summary

Christopher Holroyd, Rakhi Seth, Marwan Bukhari et al. · Lara D. Veeken · 2018 · 71 citations · Full text

British Society, Rheumatology, Rheumatoid Disorder +9